Latest Conference Articles

Patients with muscle invasive bladder cancer ineligible for cisplatin in cohort H of the phase 1b/2 EV-103 trial demonstrated promising antitumor activity when receiving neoadjuvant enfortumab vedotin.

Time to event end points and response rates were similar regardless of which first-line immunotherapy was administered, according to an analysis conducted by the International Metastatic Renal Cell Carcinoma Database Consortium

The phase 2 BAYOU study failed to meet its primary end point of improvement in progression-free survival with olaparib plus durvalumab in patients with platinum-ineligible metastatic urothelial carcinoma.

Patients with checkpoint inhibitor–naïve metastatic urothelial cancer had promising anti-tumor activity when treated with sacituzumab govitecan and pembrolizumab in the second-line setting.

New data presented during the Genitourinary Cancers Symposium support the using cabozantinib after immunotherapy without new safety signals.

Tanya Dorff, MD, discusses the current treatment modalities for prostate cancer and the hope that chimeric antigen receptor T cells will improve outcomes.

Mixed results were reported from the phase 2 ARIES clinical trial at the 2022 ASCO GU meeting.

Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.

Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT and percent change in lesion number may be associated with overall survival in patients with metastatic genitourinary malignancies.

An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.

Results from the combination of lenvatinib and pembrolizumab show similarity with the comparator in the phase 3 LEAP-011 study.

Cabozantinib administered in the neoadjuvant setting to patients with advanced renal cell carcinoma may be beneficial, but more research is needed to confirm.

Based on pooled long-term data, the safety of darolutamide is solidified in patients with metastatic castration resistant prostate cancer.

Tanya Dorff, MD, discusses the introduction of chimeric antigen receptor T-cell therapy into the prostate cancer landscape.

Utilizing 18F-rhPSMA-7.3 imaging, detection rates for prostate cancer recurrence were favorable in the phase 3 SPOTLIGHT study.

In a subgroup analysis of the ARAMIS study, the safety and efficacy of darolutamide were not impacted by patients having comorbidities and receiving concomitant medications.

According to results from the phase 3b PRESIDE trial, use of continuous enzalutamide may extend progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Results from the ARASENS trials demonstrate superior survival outcomes with darolutamide versus placebo plus androgen deprivation therapy and docetaxel.

A significant percentage of reduction in the risk of radiographic disease progression or death was observed with olaparib plus abiraterone compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer.

Phase 3 MAGNITUDE study results show positive efficacy for niraparib plus abiraterone in HRR gene-altered metastatic castration resistant prostate cancer.

A look back at apalutamide treatment in the the TITAN and SPARTAN trials showed that deep prostate-specific antigen responses lead to improvement in certain health-related quality of life factors.

According to real-world data, apalutamide may be more likely to offer an early and deep prostate-specific antigen reduction than enzalutamide.

The observational GALAXY study has shown that using a ctDNA assay may help identify which patients with colorectal cancer have the potential to derive benefit from adjuvant chemotherapy.

CheckMate 9X8 trial results indicate a progression-free survival improvement with nivolumab that was not statistically significant.

Promising study results support continued research of T-DXd in patients with HER2-positive mCRC while the risk of potential ILD/pneumonitis requires monitoring.

Afsaneh Barzi, Md, PhD, provides background on a new phase 1/2 studying exploring the combination of regorafenib and pembrolizumab in patients with refractory microsatellite stable colorectal cancer.

Patients with advanced hepatocellular carcinoma achieved notable improvements in survival and responses following treatment with transarterial chemoembolization and lenvatinib.

In a phase 1/2 study demonstrated that the combination of encorafenib, cetuximab, and nivolumab was well tolerated and led to responses in patients with microsatellite stable BRAFV600E metastatic colorectal cancer.

Results from a large trial evaluating the combination of pembrolizumab and regorafenib showed durable results for patients with microsatellite stable colorectal cancer.

Treatment with a triplet combination of pembrolizumab, binimetinib and bevacizumab was associated with an observed clinical benefit in patients with microsatellite-stable, treatment-refractory metastatic colorectal cancer.